Etid klinik pou Emofili nan Florid
6 etid pou Emofili ap chèche patisipan nan sit nan Florid.
Vil nan Florid
Tèks ofisyèl etid la (Anglè)
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- USF Health Morsani Center For Advanced Healthcare, Tampa
- The University of South Florida Board of Trustees, Tampa
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Oct 2, 2026 · NCT05568719A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- St Joseph's Children's Hospital of Tampa, Tampa
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07416604ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- University of Florida Hemophilia Treatment Center, Gainesville
- University of Miami Comprehensive Hemophilia Treatment Center, Miami
- University of Miami Hospital and Clinics, Miami
- ak 4 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Aug 17, 2026 · NCT04398628Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
- Johns Hopkins All Children's Hospital, St. Petersburg
Ap rekriteEtid obsèvasyon
Laj 6 a 19 · Tout sèks · Mizajou Jul 2, 2026 · NCT05022459Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
- University of Miami Miller School of Medicine, Miami
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 2, 2026 · NCT03695978Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
- University of Miami - Miller School of Medicine, Coral Gables
- St. Joseph's Children's Hospital - Center for Bleeding and Clotting Disorders, Tampa
Ap rekriteFaz 1
Laj 0 a 90 · Tout sèks · Mizajou Apr 3, 2026 · NCT05500807Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.